UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2177-7
Program Prior Authorization/Medical Necessity
Medication Firdapse® (amifampridine)
P&T Approval Date 11/2019, 11/2020, 11/2021, 3/2022, 11/2022, 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Firdapse (amifampridine) is a potassium channel blocker indicated for the treatment of Lambert-
Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Firdapse will be approved based on all of the following criteria:
a. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)
-AND-
b. Prescribed by or in consultation with a specialist in the treatment of LEMS (e.g.,
neurologist or oncologist)
-AND-
c. Patient is not receiving Firdapse in combination with similar potassium channel
blockers [e.g., Ampyra (dalfampridine)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Firdapse will be approved based on both the following criteria:
a. Documentation of positive clinical response to Firdapse therapy
-AND-
b. Patient is not receiving Firdapse in combination with similar potassium channel
blockers [e.g., Ampyra (dalfampridine)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
© 2024 UnitedHealthcare Services, Inc.
1
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Firdapse [package insert]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.; May 2024.
Program Prior Authorization/Medical Necessity - Firdapse (amifampridine)
Change Control
11/2019 New program
11/2020 Annual review with no changes to coverage criteria. Updated
references.
11/2021 Annual review with no changes to coverage criteria. Updated
references.
3/2022 Removed step through Ruzurgi due to FDAs conversion of Ruzurgi
from full approval to tentative approval.
11/2022 Updated background to reflect new pediatric indication for patients 6
years of age and older.
11/2023 Added “Diagnosis of” to initial criteria with no change to clinical intent.
11/2024 Annual review with no changes to coverage criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2